APA (7th ed.) Citation

Yu, J., Li, M., Zhu, Y., Wang, S., Jiang, Y., Cui, W., & Wu, L. (2026). Toward the precision use of Chinese PARP inhibitors in ovarian cancer: Clinical progress, resistance mechanisms, and future perspectives. Cancer Biology & Medicine, 23(6), 788. https://doi.org/10.20892/j.issn.2095-3941.2026.0102

Chicago Style (17th ed.) Citation

Yu, Jing, Maochen Li, Yuhan Zhu, Shengnan Wang, Yuzhao Jiang, Wei Cui, and Lingying Wu. "Toward the Precision Use of Chinese PARP Inhibitors in Ovarian Cancer: Clinical Progress, Resistance Mechanisms, and Future Perspectives." Cancer Biology & Medicine 23, no. 6 (2026): 788. https://doi.org/10.20892/j.issn.2095-3941.2026.0102.

MLA (9th ed.) Citation

Yu, Jing, et al. "Toward the Precision Use of Chinese PARP Inhibitors in Ovarian Cancer: Clinical Progress, Resistance Mechanisms, and Future Perspectives." Cancer Biology & Medicine, vol. 23, no. 6, 2026, p. 788, https://doi.org/10.20892/j.issn.2095-3941.2026.0102.